Reed F Beall, Tali Glazer, Haris Ahmad, Mikayla Buell, Slane Hahn, Adam R Houston, Aaron S Kesselheim, Jason W Nickerson, Warren Kaplan
{"title":"Patent \"Evergreening\" of Medicine-Device Combination Products: A Global Perspective.","authors":"Reed F Beall, Tali Glazer, Haris Ahmad, Mikayla Buell, Slane Hahn, Adam R Houston, Aaron S Kesselheim, Jason W Nickerson, Warren Kaplan","doi":"10.12927/hcpol.2022.26973","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patenting medicine-delivery devices (inhalers and pens) is controversial when it extends market protections beyond that of the underlying therapeutic agent. We evaluated how common device patenting is, internationally.</p><p><strong>Method: </strong>Using a product sample (n = 88) and an international patent database, we assessed the issue's scope.</p><p><strong>Results: </strong>When comparing the 88 patent portfolios for each product in each country, Canada was found to be among the most impacted, with 90% of the portfolios containing at least one device patent and 35% of the portfolios containing device patents exclusively.</p><p><strong>Conclusion: </strong>Patenting of delivery devices impacts major pharmaceutical manufacturing centres worldwide. International consensus among stakeholders (regulators and payors) is needed on which device modifications represent meaningful clinical value.</p>","PeriodicalId":39389,"journal":{"name":"Healthcare Policy","volume":"18 2","pages":"14-26"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764446/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Healthcare Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12927/hcpol.2022.26973","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Patenting medicine-delivery devices (inhalers and pens) is controversial when it extends market protections beyond that of the underlying therapeutic agent. We evaluated how common device patenting is, internationally.
Method: Using a product sample (n = 88) and an international patent database, we assessed the issue's scope.
Results: When comparing the 88 patent portfolios for each product in each country, Canada was found to be among the most impacted, with 90% of the portfolios containing at least one device patent and 35% of the portfolios containing device patents exclusively.
Conclusion: Patenting of delivery devices impacts major pharmaceutical manufacturing centres worldwide. International consensus among stakeholders (regulators and payors) is needed on which device modifications represent meaningful clinical value.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
